The Free, Open Source, Copyleft Textbook wikidoc.org edited by Thousands of Doctors Millions of times that I founded in 2006 had 85.9 Million page views last month with an annualized rate over 1 billion views per year wikidoc.org !

What if there was a ONCE A YEAR subcutaneous injection to lower blood pressure and reduce cholesterol ? Drs. Maraganore,  Meanwell and I discuss an exciting new therapy that may just do that!

Wonderful interview C. Michael Gibson MD -- no doubt that prevention efforts need to start earlier, and that we need innovative approaches & trials in this space!

Rembrandt at age 34. Oil on 24 x 36 canvas by C. Michael Gibson September 20, 2025. At 34 he saw like no one else. It took days to just do the eyes that saw so well #cmgsays #cmgsees better after staring at this for a month #artistsoftwitter

Dr. Secemsky and I discuss the evolving PAD guidelines, which now highlight critical insights on health disparities, updated therapeutic strategies, and exercise recommendations.

Dr. Lakdawala, Dr. Januzzi and I discuss the findings were presented today at HFSA from the phase 2a clinical trial of danicamtiv in patients with genetic DCM clinicaltrialresults.org/dr-lakdawala-d…

Dr. Belardo and I discuss: The Target is the Plaque: Stabilization, Regression, and the Role of Imaging and AI in Modern CAD Management s/b Cleerly Women As One and International Atherosclerosis Society (IAS) clinicaltrialresults.org/dr-danielle-be…

The recording from today’s Baim Grand Rounds and Inaugural Gibson Lecture in Leadership with Dr. Robert Harrington on “Leadership in Academic Medicine: Lessons, Challenges, and Opportunities” is now available on the Baim website. You can view it here: baiminstitute.org/index.php/lead…

My journey from being a kid in a small town in Oklahoma who wanted to be a stock car driver to creating a free open source textbook that is viewed a billion times a year ( wikidoc.org ). medstorymedia.com/podcast

The goal is to allow “Good clots” that prevent bleeding to form but inhibit “bad clots” that form inside the vessel with factor xi inhibition

The press in Argentina covered my talk yesterday Un experto de Harvard anticipó la nueva era de la medicina: “El futuro de los ensayos clínicos será virtual” - Infobae infobae.com/salud/2025/10/…

Honored to receive the ZKAM Award for Outstanding Contributions to Acute Cardiovascular Research from the Centre for Cardiovascular Acute Medicine Mannheim. Grateful to the colleagues, mentors, and patients who continue to inspire this work every day.

RCT_Eval (1): SLIM trial FFR-guided complete PCI reduced 1-year MACE (5.5% vs 13.6%) 🔹 Very slow recruitment/lack of screening → strong selection bias 🔹 Open-label + “any revascularization” → bias-prone endpoint Apparent benefit may reflect methodological artifact, not true

jamanetwork.com/journals/jama/…

"Medical community needs to be engaged in promoting healthspan and not just lifespan" 🔥MGB Cardiology Grand Rounds by the extraordinary Prof. John Deanfield 👉Obesity is a chronic multifactorial, relapsing disease 👉Rx treat not just obesity..multiple disease & ageing

Spotlight 🔦on the Baim Institute Imaging Core Lab!

Dr. Ruben de Winter and Dr. C. Michael Gibson discuss the PROCTOR trial: Does PCI of the SVG improve CV outcomes vs. PCI of the native vessel in post-CABG patients with graft failure? #TCT2025 View it Here: clinicaltrialresults.org/wp-content/upl…

STRIVE trial: Adjunctive intracoronary low-dose t-PA during primary PCI did not improve microvascular obstruction or 30-day MACE vs. placebo in STEMI patients with large thrombus burden. #TCT2025 View it here: clinicaltrialresults.org/wp-content/upl…

Dr. Ron Blankstein addresses strengths and gaps of current CV risk models during the Advanced CV Risk Detection For the Critical Decades Roundtable. bit.ly/4oE6gw4 #TransformCVCare #cvPrev

New evidence on balloon-based strategies for calcified coronary lesions was presented at #TCT2025 (ShortCut and Victory trials). With proper imaging and sizing, OPN and cutting balloons can achieve outcomes comparable to IVL — often at a lower cost. metastata.substack.com/p/approach-to-…